ARGENX SE

Argenx announced it will host a conference call and audio webcast on Thursday, July 23, 2026, at 2:30 p.m. CET (8:30 a.m. ET). The call will cover the company's half-year 2026 financial results and provide a second-quarter business update. Investors can access the live webcast on the company's website or join via provided dial-in numbers.

Argenx, a global immunology company, announced it will host an R&D webinar today, June 23, 2026, at 2:00 PM ET. The webinar, titled "R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis," will feature argenx management and scientific leadership alongside external key opinion leaders. A live webcast and supporting presentation slides will be available on the company's investor relations website.

Argenx presented new efgartigimod data at EULAR 2026, demonstrating long-term sustained patient benefit and a consistent safety profile in myositis and Sjogren's disease. The ALKIVIA+ open-label extension study showed sustained clinically meaningful improvements in myositis patients, with 37.5% maintaining major TIS improvement at 52 weeks. The RHO+ study indicated maintenance of response in Sjogren's disease patients following a switch to biweekly dosing, with low median ClinESSDAI scores at Week 72. A cross-indication safety analysis reinforced efgartigimod's well-tolerated profile across multiple autoimmune rheumatic diseases.

Argenx announced new data at EULAR 2026 for efgartigimod in autoimmune rheumatic diseases, including myositis and Sjogren's disease. The ALKIVIA+ open-label extension study in myositis showed sustained, clinically meaningful improvements and a consistent safety profile through 52 weeks. The RHO+ open-label extension study in Sjogren's disease indicated maintenance of response following a switch to biweekly dosing. A cross-indication analysis reinforced efgartigimod's consistent safety profile across a large patient population.

argenx announced it will host a webinar titled "R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis" on Tuesday, June 23, 2026, at 2:00pm ET. This webinar is part of a 'mini' series highlighting the company's pipeline and R&D strategy, focusing on myositis, a severe autoimmune rheumatic disease. The event will feature discussions on disease biology, the ALKIVIA clinical program design, and the clinical and commercial potential of efgartigimod.

argenx announced that members of its management team will participate in two investor conferences in June 2026. They will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026, and hold a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Live webcasts and replays will be available on the company's investor relations website.

Argenx announced that the U.S. FDA approved a label expansion for VYVGART and VYVGART Hytrulo for the treatment of all serotypes of adult patients with generalized myasthenia gravis (gMG). This approval is based on data from the Phase 3 ADAPT SERON study, which showed rapid, significant, and sustained symptom improvements across anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients. The expanded indication simplifies treatment decisions for clinicians and addresses a significant unmet medical need for gMG patients without detectable AChR antibodies.

argenx SE reported strong first-quarter 2026 financial results, with global product net sales increasing 63% year-over-year to $1.3 billion and operating profit surging 183% to $394 million. The company also provided a positive business update, highlighting the upcoming PDUFA decision for seronegative gMG on May 10, 2026, and several pipeline advancements. Key leadership changes included Karen Massey's appointment as CEO and Tim Van Hauwermeiren as Chairperson of the Board.

argenx announced that its Chief Executive Officer, Karen Massey, will present at the BofA Securities 2026 Health Care Conference. The presentation is scheduled for Tuesday, May 12, 2026, at 10:40 a.m. PT. Investors can access a live webcast and a subsequent replay for about 30 days on the company's investor relations website.

argenx SE announced a leadership transition following its Annual General Meeting. Karen Massey, previously Chief Operating Officer, has been appointed Chief Executive Officer, succeeding co-founder Tim Van Hauwermeiren. Mr. Van Hauwermeiren will now serve as Chairperson of the Board of Directors. The AGM also approved the 2025 remuneration report, annual report, profit allocation, and authorized the issuance of up to 10% of the company's share capital.